Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2027

Conditions
Glioma
Interventions
DRUG

Hyperpolarized 13C-Pyruvate

"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."

Trial Locations (1)

21201

RECRUITING

Rosy Njonkou Tchoquessi, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER